MarketInOut Stock Screener Log In | Sign Up
 

Almirall S.A.

BME • Healthcare • Drug Manufacturers - Specialty & Generic • Quote as of 07/27/2026 17:35
Almirall S.A. stock price and volume chart

Company Profile

IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeBME
Market Capitalization2,437.36 mln
Float78.98 mln
Earnings Date07/24/2026

EPS

0.28
Overpriced

P / E

40.29
High premium

Piotroski F-Score

7 / 9
Strong

Beneish M-Score

-2.71
Likely reliable

1-Year Forecast

14.51
Strong upside

Relative Strength

77 / 100
Strongly outperforming

Business Description

Almirall S.A. is a Spanish biopharmaceutical company founded in 1943 and headquartered in Barcelona, with operations spanning Europe, the United States, the Middle East, Asia, and Africa. The company focuses primarily on treating skin conditions such as psoriasis, acne, and atopic dermatitis, while also offering products that address a broader range of medical areas including cardiovascular, respiratory, and nervous system disorders. Almirall has a growing pipeline of experimental treatments at various stages of development, targeting conditions such as hidradenitis suppurativa, alopecia areata, and skin cancer. The company collaborates with several external research partners, including Novo Nordisk and Evotec, to advance its drug discovery and development efforts.

Key Fundamentals

EPS0.28
P/E40.29
ROE3.52
RPS6.33
ROIC3.09
ROA2.23
Interest Cover4.34
EBITDA, mln299
EV / EBITDA8.16
EV / EBIT23.32
Revenue, mln1,375
EV / Revenue1.77

Financial Strength

Altman Z-Score2.72
Piotroski F-Score 7 / 9
Beneish M-Score-2.71
Price to Intrinsic Value1.54
Price to Lynch Fair Value8.48
Price to Graham Number4.50
1-Year Target Price14.51

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 2.93% 67 / 100   
1 Month -0.18% 45 / 100   
2 Months -10.06% 22 / 100   
6 Months -10.78% 19 / 100   
1 Year 5.53% 42 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us